Danaher (DHR)
(Delayed Data from NYSE)
$269.23 USD
+0.42 (0.16%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $269.07 -0.16 (-0.06%) 6:18 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$269.23 USD
+0.42 (0.16%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $269.07 -0.16 (-0.06%) 6:18 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).
Should You Invest in the Invesco Global Water ETF (PIO)?
by Zacks Equity Research
Sector ETF report for PIO
Should You Invest in the Invesco Water Resources ETF (PHO)?
by Zacks Equity Research
Sector ETF report for PHO
The Zacks Analyst Blog Highlights Walmart, Exxon Mobil, Danaher and GSI Technology
by Zacks Equity Research
Walmart, Exxon Mobil, Danaher and GSI Technology are part of the Zacks top Analyst Blog.
Top Stock Reports for Walmart, Exxon Mobil & Danaher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Exxon Mobil Corporation (XOM) and Danaher Corporation (DHR), as well as a micro-cap stock GSI Technology, Inc. (GSIT).
Here's Why Hold Strategy Is Apt for Danaher (DHR) Stock Now
by Zacks Equity Research
Strength in the Life Sciences segment augurs well for Danaher (DHR). The company's measures to reward its shareholders are promising.
Why Is Danaher (DHR) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
by Zacks Equity Research
UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.
Top Stock Reports for UnitedHealth, Danaher & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).
Danaher (DHR) Rides on Business Strength Amid Headwinds
by Zacks Equity Research
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
by Zacks Equity Research
Markel (MKL) first-quarter results reflect improved earned premiums and increased net investment income.
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
by Zacks Equity Research
Honeywell's (HON) first-quarter 2024 revenues increase approximately 3%, driven by strong momentum in the Aerospace Technologies segment.
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
by Zacks Equity Research
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
by Zacks Equity Research
While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 11.63% and 2.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Honeywell (HON) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Honeywell's (HON) first-quarter results are likely to have benefited from strength across most of its businesses. Weakness in the warehouse automation market might have been a spoilsport.
Why Danaher (DHR) Might Surprise This Earnings Season
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
Carlisle (CSL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Carlisle (CSL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Danaher (DHR) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.